Canada is facing a major drug shortage problem and authorities must do more to notify patients when supplies of the medications they rely on are dwindling, as well as investigate the causes of the shortages, says the president of the Canadian Medical Association, Dr. Louis Hugo Francescutti.
Read more about his interview below as he appeared on Canada AM, Wednesday, June 25, 2014.
Epilepsy Durham Region and Epilepsy Ontario are proud to present the premiere screening of the documentary, On the Edge: Living with Epilepsy at the Abilities Centre (55 Gordon Street, Whitby), on June 25, 2014. The film screening will include a facilitated conversation with a medical clinician, an individual who lives with epilepsy and other notable guests followed by a reception.
Show your support. Together, we can, indeed we are, making a difference in improving the quality of life for people with epilepsy. Doors open at 6:00pm, followed by a screening of the film at 6:45pm and panel discussion at 7:40pm.
In consultation with Health Canada, four companies (Cobalt Pharmaceuticals, Laboratoire Riva, Mylan Pharmaceuticals and Sanis Health) are voluntarily recalling various lots of five prescription drugs (amlodipine, ciprofloxacin, lamotrigine, norfloxacin and telmisartan) from the Canadian market (see chart below). The voluntary recall is a precautionary measure due to quality concerns at the manufacturing facility of the active ingredients used in the products. The issues are primarily around processes that affect quality control and oversight.
To read the full article, click here.
ONE in 20 children whose mothers used a drug to treat epilepsy during pregnancy suffers from an autistic disorder, research suggests.
A study involving 655,615 children born between 1996 and 2006 found that 4.42 per cent of those whose mothers used the drug valproate while pregnant were diagnosed with an autism- spectrum disorder, which can range from mild to more severe forms. The research also found that 2.5 per cent were found to have childhood autism.
Please click hereto read the full story and learn more about the research conducted.
Please find the attached stakeholder information package for the Canada/U.S. Medical Reciprocity Agreement for Commercial Drivers (W Code). It contains a stakeholder letter, a sample of the notificaion letter sent to drives, and a question and answer sheet.